This sd-LDL outcome (36.1 ± 14.9 mg/dl at 52 weeks) was significantly lower than those in the DST Group (45.6 ± 13.4 mg/dl at 52wk). The sd-LDL-C level at 52wks were significantly different (p = 0.0035). (Fig. 3C)
ezetimibe (10 mg) add-on statin (EAT)
double-dose statin (DST) 
Small dense low-density lipoprotein cholesterol (sd-LDL-C) level at 52wks